JAMA · 1934 · 38 citations · 2 references
MedicineMedicinal ChemistryPharmacologyAnesthesiaExperimental PharmacologyGeneral PharmacologyHypnotic AgentsHypnotic PharmacotherapyHypnotic TherapySedative PharmacologyBarbiturate PoisoningBarbiturate TherapyHypnotic EffectsHypnotic MedicationsOrganic SaltsPhenobarbital TherapyPhenobarbital Use
In 1903, Fischer and von Mering 1 described the barbituric acid hypnotic diethylbarbituric acid (diethyl malonyl urea), introduced as Veronal. This is now official in the United States Pharmacopeia X as barbital. There were also introduced the sodium salts of barbital under the proprietary names Medinal and Veronal Sodium. Some years later a second derivative of the series was announced; in this, one of the ethyl groups was displaced by a phenyl group. This derivative, phenylethylbarbituric acid, was the proprietary designated as Luminal; the same substance is now official under the name phenobarbital. In the meantime, numerous hypnotics of the barbituric acid series 2 in which the ethyl groups are replaced by other alkyl or aryl radicals have been developed, including, among the more common ones, amytal (isoamylethylbarbituric acid), dial (diallylbarbituric acid), neonal (N-butylethylbarbituric acid), nostal (isopropyl bromallyl barbituric acid) and pentobarbital sodium. In February, 1922, Allonal (Numal) was introduced
2
Fred Wise · Archives of Dermatology and Syphilology · 1933 · 64 citations